Maturation inhibitors: a new therapeutic class targets the virus structure.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  AIDS Reviews

• Publication date

  2007-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 17982941
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multiple-Dose Pharmacokinetics and Safety of Bevirimat, a Novel Inhibitor of HIV Maturation, in Healthy Volunteers

  2007cited by this paper
• Glucuronidation of Anti-HIV Drug Candidate Bevirimat: Identification of Human UDP-glucuronosyltransferases and Species Differences

  2007cited by this paper
• Mortality after myocardial infarction in HIV-infected patients who have initiated HAART

  2007cited by this paper
• Electron cryotomography of immature HIV‐1 virions reveals the structure of the CA and SP1 Gag shells

  2007cited by this paper
• In Vitro Resistance to the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PA-457 (Bevirimat)

  2006cited by this paper
• Synthesis and anti-HIV activity of bi-functional betulinic acid derivatives.

  2006cited by this paper
• Determinants of activity of the HIV-1 maturation inhibitor PA-457.

  2006cited by this paper
• 3-O-(3′,3′-Dimethysuccinyl) Betulinic Acid Inhibits Maturation of the Human Immunodeficiency Virus Type 1 Gag Precursor Assembled In Vitro

  2006cited by this paper
• Structural Characterization of Anti-HIV Drug Candidate PA-457 [3-O-(3′,3′-Dimethylsuccinyl)-betulinic acid] and Its Acyl Glucuronides in Rat Bile and Evaluation of in Vitro Stability in Human and Animal Liver Microsomes and Plasma

  2006cited by this paper
• Human Immunodeficiency Virus Type 1 Resistance to the Small Molecule Maturation Inhibitor 3-O-(3′,3′-Dimethylsuccinyl)-Betulinic Acid Is Conferred by a Variety of Single Amino Acid Substitutions at the CA-SP1 Cleavage Site in Gag

  2006cited by this paper
• Anti-AIDS agents 69. Moronic acid and other triterpene derivatives as novel potent anti-HIV agents.

  2006cited by this paper
• Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates

  2005cited by this paper
• Three-dimensional structure of HIV-1 virus-like particles by electron cryotomography.

  2005cited by this paper
• Ordered Processing of the Human Immunodeficiency Virus Type 1 GagPol Precursor Is Influenced by the Context of the Embedded Viral Protease

  2005cited by this paper
• Betulinic acid derivatives as HIV-1 antivirals.

  2005cited by this paper
• Inhibition of HIV-1 Maturation via Drug Association with the Viral Gag Protein in Immature HIV-1 Particles*

  2005cited by this paper
• Helical structure determined by NMR of the HIV‐1 (345–392)Gag sequence, surrounding p2: Implications for particle assembly and RNA packaging

  2005cited by this paper
• HIV-1 assembly and budding as targets for drug discovery.

  2005cited by this paper
• Initial Cleavage of the Human Immunodeficiency Virus Type 1 GagPol Precursor by Its Activated Protease Occurs by an Intramolecular Mechanism

  2004cited by this paper
• The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid

  2004cited by this paper
• The stoichiometry of Gag protein in HIV-1

  2004cited by this paper
• Small-Molecule Inhibition of Human Immunodeficiency Virus Type 1 Replication by Specific Targeting of the Final Step of Virion Maturation

  2004cited by this paper
• Bifunctional Anti-Human Immunodeficiency Virus Type 1 Small Molecules with Two Novel Mechanisms of Action

  2004cited by this paper
• Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection

  2004cited by this paper
• Assembly Properties of the Human Immunodeficiency Virus Type 1 CA Protein

  2004cited by this paper
• The molecular basis of HIV capsid assembly—five years of progress

  2004cited by this paper
• Flexibility in the P2 domain of the HIV‐1 Gag polyprotein

  2004cited by this paper
• Identification of novel interactions in HIV-1 capsid protein assembly by high-resolution mass spectrometry.

  2003cited by this paper
• PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing

  2003cited by this paper
• Structural organization of authentic, mature HIV‐1 virions and cores

  2003cited by this paper
• How does your virus grow? Understanding and interfering with virus assembly.

  2003cited by this paper
• Replacement of the P1 Amino Acid of Human Immunodeficiency Virus Type 1 Gag Processing Sites Can Inhibit or Enhance the Rate of Cleavage by the Viral Protease

  2002cited by this paper
• Characterization of a Putative α-Helix across the Capsid-SP1 Boundary That Is Critical for the Multimerization of Human Immunodeficiency Virus Type 1 Gag

  2002cited by this paper
• The Mason-Pfizer Monkey Virus Internal Scaffold Domain Enables In Vitro Assembly of Human Immunodeficiency Virus Type 1 Gag

  2002cited by this paper
• Anti-AIDS agents 49. Synthesis, anti-HIV, and anti-fusion activities of IC9564 analogues based on betulinic acid.

  2002cited by this paper
• Modulation of HIV-like particle assembly in vitro by inositol phosphates

  2001cited by this paper
• Characterization of Rous Sarcoma Virus Gag Particles Assembled In Vitro

  2001cited by this paper
• Organization of Immature Human Immunodeficiency Virus Type 1

  2001cited by this paper
• Anti-Human Immunodeficiency Virus Activity of YK-FH312 (a Betulinic Acid Derivative), a Novel Compound Blocking Viral Maturation

  2001cited by this paper
• Biochemical and Structural Analysis of Isolated Mature Cores of Human Immunodeficiency Virus Type 1

  2000cited by this paper
• Image reconstructions of helical assemblies of the HIV-1 CA protein

  2000cited by this paper
• Synthesis and anti-HIV activity of 3-alkylamido-3-deoxy-betulinic acid derivatives.

  2000cited by this paper
• A conformational switch controlling HIV‐1 morphogenesis

  2000cited by this paper
• Assembly and analysis of conical models for the HIV-1 core.

  1999cited by this paper
• Anti-AIDS agents. 30. Anti-HIV activity of oleanolic acid, pomolic acid, and structurally related triterpenoids.

  1998cited by this paper
• N-Terminal Extension of Human Immunodeficiency Virus Capsid Protein Converts the In Vitro Assembly Phenotype from Tubular to Spherical Particles

  1998cited by this paper
• Proteolytic refolding of the HIV‐1 capsid protein amino‐terminus facilitates viral core assembly

  1998cited by this paper
• Anti-AIDS agents. 34. Synthesis and structure-activity relationships of betulin derivatives as anti-HIV agents.

  1998cited by this paper
• Sequential Steps in Human Immunodeficiency Virus Particle Maturation Revealed by Alterations of Individual Gag Polyprotein Cleavage Sites

  1998cited by this paper
• Supramolecular organization of immature and mature murine leukemia virus revealed by electron cryo-microscopy: implications for retroviral assembly mechanisms.

  1998cited by this paper
• Inhibiting virus-capsid assembly by altering the polymerisation pathway.

  1998cited by this paper
• A Putative α-Helical Structure Which Overlaps the Capsid-p2 Boundary in the Human Immunodeficiency Virus Type 1 Gag Precursor Is Crucial for Viral Particle Assembly

  1998cited by this paper
• In vitro assembly of virus-like particles with Rous sarcoma virus Gag deletion mutants: identification of the p10 domain as a morphological determinant in the formation of spherical particles

  1997cited by this paper
• Synthesis, Assembly, and Processing of Viral Proteins

  1997cited by this paper
• Cryo-electron microscopy reveals ordered domains in the immature HIV-1 particle.

  1997cited by this paper
• Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein.

  1997cited by this paper
• Retroviral Virions and Genomes

  1997cited by this paper
• In vitro assembly properties of purified bacterially expressed capsid proteins of human immunodeficiency virus.

  1997cited by this paper
• Anti-AIDS agents--XXVII. Synthesis and anti-HIV activity of betulinic acid and dihydrobetulinic acid derivatives.

  1997cited by this paper
• A Multistep, ATP-dependent Pathway for Assembly of Human Immunodeficiency Virus Capsids in a Cell-free System

  1997cited by this paper
• Triterpenes as potential dimerization inhibitors of HIV-1 protease.

  1996cited by this paper
• Proteolytic processing and particle maturation.

  1996cited by this paper
• Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents.

  1996cited by this paper
• Crystal structure of dimeric HIV-1 capsid protein

  1996cited by this paper
• Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis

  1995cited by this paper
• The spacer peptide between human immunodeficiency virus capsid and nucleocapsid proteins is essential for ordered assembly and viral infectivity

  1995cited by this paper
• Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1

  1995cited by this paper
• The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions

  1994cited by this paper
• Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids.

  1994cited by this paper
• Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells.

  1994cited by this paper
• Assembly of recombinant human immunodeficiency virus type 1 capsid protein in vitro

  1992cited by this paper

• Structural Basis for HIV-1 Maturation Inhibition by PF-46396 Determined by MAS NMR.

  2025cites this paper
• Structural Basis for HIV-1 Maturation Inhibition by PF-46396 Determined by MAS NMR

  2025cites this paper
• Structural basis of HIV-1 maturation inhibitor binding and activity

  2022cites this paper
• Occupation of a thermoresistant-scaffold (αRep) at SP1-NC cleavage site disturbs the function of HIV-1 protease

  2020cites this paper
• Combination of drug and stem cells neurotherapy: Potential interventions in neurotrauma and traumatic brain injury

  2019cites this paper
• Betulin and its derivatives – precursors of new drugs

  2019cites this paper
• Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial

  2018cites this paper
• Resistance to Second-Generation HIV-1 Maturation Inhibitors

  2018cites this paper
• Stem cells and combination therapy for the treatment of traumatic brain injury

  2018cites this paper
• Prodrugs of triterpenoids and their derivatives.

  2017cites this paper
• Structural biology of supramolecular assemblies by magic-angle spinning NMR spectroscopy

  2017cites this paper
• The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor–Resistant Clinical Isolates

  2017cites this paper
• Current Approaches in Computational Drug Resistance Prediction in HIV.

  2016cites this paper
• Contributions of Charged Residues in Structurally Dynamic Capsid Surface Loops to Rous Sarcoma Virus Assembly

  2016cites this paper
• Characterization of New Cationic N,N-Dimethyl[70]fulleropyrrolidinium Iodide Derivatives as Potent HIV-1 Maturation Inhibitors.

  2016cites this paper
• Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors

  2016cites this paper
• C-3 benzoic acid derivatives of C-3 deoxybetulinic acid and deoxybetulin as HIV-1 maturation inhibitors.

  2016cites this paper
• Functional and clinical consequences of immune-driven sequence variation of gag-protease in HIV-1 subtypes A, C, D and recombinants.

  2016cites this paper
• Maturation Inhibitor with Improved Potency, Anti-viral Spectrum and Gag Polymorphic

  2016cites this paper
• Mathematical modelling of host-disease-drug interactions in HIV disease

  2016cites this paper
• Defining and characterizing the step in the HIV-1 viral life cycle affected by fullerene derivatives

  2016influential citation
• SHIVA - a web application for drug resistance and tropism testing in HIV

  2016cites this paper
• The role of the HIV-1 protease substrate in therapy resistance

  2015cites this paper
• Pharmacological intervention of HIV-1 maturation

  2015cites this paper
• The impact of a UK HIV-1 resistance database for the management and improvement of the clinical care of people living with HIV-1

  2015cites this paper
• Identification of an HIV-1 Mutation in Spacer Peptide 1 That Stabilizes the Immature CA-SP1 Lattice

  2015cites this paper
• HIV-1 assembly, release and maturation

  2015cites this paper
• Aptamers, a New Class of Binders, with Particular Focus on Diagnostics and Bioactivity in the Field of Virology

  2014cites this paper
• In Vitro Analysis of Human Immunodeficiency Virus Particle Dissociation: Gag Proteolytic Processing Influences Dissociation Kinetics

  2014cites this paper
• Dynamic and geometric analyses of Nudaurelia capensis ω virus maturation reveal the energy landscape of particle transitions

  2014cites this paper
• The effect of antiretrovirals on myoblast proliferation : migration and differentation.

  2013cites this paper
• Functional conservation of HIV-1 Gag: implications for rational drug design

  2013cites this paper
• Magic angle spinning NMR reveals sequence-dependent structural plasticity, dynamics, and the spacer peptide 1 conformation in HIV-1 capsid protein assemblies.

  2013cites this paper
• Targets for Inhibition of HIV Replication: Entry, Enzyme Action, Release and Maturation

  2012cites this paper
• Molecular recognition in the human immunodeficiency virus capsid and antiviral design.

  2012cites this paper
• Antiretroviral drugs: Critical issues and recent advances

  2012cites this paper
• Triterpenoids for cancer prevention and treatment: current status and future prospects.

  2012cites this paper
• Determinants of the Development and Evolution of HIV-1 Drug Resistance

  2012cites this paper
• Improved Bevirimat resistance prediction by combination of structural and sequence-based classifiers

  2011cites this paper
• HIV‐1 Protease: Role in Viral Replication, Protein–Ligand X‐Ray Crystal Structures and Inhibitor Design

  2011cites this paper
• Morphogenesis of the Infectious HIV-1 Virion

  2011cites this paper
• The Emergence of Small-Molecule Inhibitors of Capsid Assembly as Potential Antiviral Therapeutics

  2011cites this paper
• Structure and stoichiometry of template-directed recombinant HIV-1 Gag particles.

  2011cites this paper
• Advances in the synthesis and pharmacological activity of lupane-type triterpenoid saponins

  2011cites this paper
• The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles

  2011cites this paper
• Bioinformatical approaches to ranking of anti-HIV combination therapies and planning of treatment schedules

  2010cites this paper
• Results Development of a detailed model of viral life cycle and action of anti-retroviral drugs

  2010cites this paper
• Novel approaches to inhibiting HIV-1 replication.

  2010cites this paper
• FIV Gag: virus assembly and host-cell interactions.

  2010cites this paper
• High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates

  2010cites this paper
• Researchin Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1maturation inhibitor bevirimat

  2010cites this paper
• Introduction to Viruses and Viral Diseases

  2010cites this paper
• A simple fluorescence based assay for quantification of human immunodeficiency virus particle release

  2010cites this paper
• Last Stop Before Exit – Hepatitis C Assembly and Release as Antiviral Drug Targets

  2010cites this paper
• Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database

  2010cites this paper
• Drug-Class Specific Impact of Antivirals on the Reproductive Capacity of HIV

  2010cites this paper
• Predicting Bevirimat resistance of HIV-1 from genotype

  2010influential citation
• Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1maturation inhibitor bevirimat

  2010cites this paper
• Can the further clinical development of bevirimat be justified?

  2010cites this paper
• High-throughput screening using pseudotyped lentiviral particles: a strategy for the identification of HIV-1 inhibitors in a cell-based assay.

  2009cites this paper
• Virus maturation as a new HIV-1 therapeutic target

  2009influential citation
• New Small-Molecule Inhibitor Class Targeting Human Immunodeficiency Virus Type 1 Virion Maturation

  2009cites this paper
• Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets.

  2009cites this paper
• Cloning and characterization of MRI, a modulator of retroviral infection

  2009cites this paper
• Impact of Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors on Evolution of Resistance to the Maturation Inhibitor Bevirimat (PA-457)

  2009cites this paper
• Susceptibility of Human Immunodeficiency Virus Type 1 to the Maturation Inhibitor Bevirimat Is Modulated by Baseline Polymorphisms in Gag Spacer Peptide 1

  2009cites this paper
• HIV-1 Gag Processing Intermediates Trans-dominantly Interfere with HIV-1 Infectivity*

  2009cites this paper
• HIV/AIDS: recent advances in antiretroviral agents.

  2009cites this paper
• Synthesis of betulinic acid acyl glucuronide for application in anticancer prodrug monotherapy

  2009cites this paper
• Characterisation of llama antibody fragments able to act as HIV-1 entry inhibitors

  2009cites this paper
• Lipid raft-based strategies to interfere with HIV-1 infection

  2009cites this paper
• Combination Therapies for Traumatic Brain Injury: Prospective Considerations

  2009cites this paper
• No exit: targeting the budding process to inhibit filovirus replication.

  2009cites this paper
• [The HIV replication cycle. Established therapeutic targets and potential targets].

  2008cites this paper
• Amélioration du comportement biopharmaceutique de triterpènes naturels anticancéreux par synthèse de saponines mono- et bidesmosidiques

  2008cites this paper
• Ciclo replicativo del VIH. Dianas terapéuticas consolidadas y dianas potenciales

  2008cites this paper
• Genetic aspects of HIV-1 evolution and transmission

  2008cites this paper
• Recent progress in antiretrovirals--lessons from resistance.

  2008cites this paper
• Macrophage-targeted nanocarriers for anti-HIV therapy

  2007cites this paper
• Natural products to drugs: natural product-derived compounds in clinical trials.

  2005cites this paper